JP7641234B2 - パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ - Google Patents

パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ Download PDF

Info

Publication number
JP7641234B2
JP7641234B2 JP2021563212A JP2021563212A JP7641234B2 JP 7641234 B2 JP7641234 B2 JP 7641234B2 JP 2021563212 A JP2021563212 A JP 2021563212A JP 2021563212 A JP2021563212 A JP 2021563212A JP 7641234 B2 JP7641234 B2 JP 7641234B2
Authority
JP
Japan
Prior art keywords
propyl
oxy
quinolin
compound
octahydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563212A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020234274A5 (https=
JP2022533913A5 (https=
JP2022533913A (ja
Inventor
ユルゲンセン，モーテン
ユール，マーティン
ジェンセン，クロース，ギジェルヴィグ
クヴェルノ，リスベット
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2022533913A publication Critical patent/JP2022533913A/ja
Publication of JPWO2020234274A5 publication Critical patent/JPWO2020234274A5/ja
Publication of JP2022533913A5 publication Critical patent/JP2022533913A5/ja
Application granted granted Critical
Publication of JP7641234B2 publication Critical patent/JP7641234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021563212A 2019-05-21 2020-05-19 パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ Active JP7641234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201900608 2019-05-21
DKPA201900608 2019-05-21
PCT/EP2020/063914 WO2020234274A1 (en) 2019-05-21 2020-05-19 New catecholamine prodrugs for use in the treatment of parkinson's disease

Publications (4)

Publication Number Publication Date
JP2022533913A JP2022533913A (ja) 2022-07-27
JPWO2020234274A5 JPWO2020234274A5 (https=) 2023-05-18
JP2022533913A5 JP2022533913A5 (https=) 2023-05-18
JP7641234B2 true JP7641234B2 (ja) 2025-03-06

Family

ID=70857151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563212A Active JP7641234B2 (ja) 2019-05-21 2020-05-19 パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ

Country Status (5)

Country Link
US (1) US12384765B2 (https=)
EP (1) EP3972970A1 (https=)
JP (1) JP7641234B2 (https=)
CN (1) CN113727979B (https=)
WO (1) WO2020234274A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
CN116568672B (zh) 2020-11-17 2026-03-24 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP2025514341A (ja) 2022-04-25 2025-05-02 インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー 新規１，２，３，４，４ａ，５，６，７，８，９，１０，１０ａ－ドデカヒドロベンゾ［Ｇ］キノリン－６－オール化合物及びその使用
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
CN119053585A (zh) 2022-04-25 2024-11-29 综合研究实验室瑞典股份公司 新颖1,2,3,4,4a,5,6,7,8,9,10,10a-十二氢苯并[G]喹啉-6-醇酯化合物及其用途
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101917A1 (en) 2017-11-24 2019-05-31 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234271A1 (en) 2019-05-20 2020-11-26 H. Lundbeck A/S A process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
WO2020234272A1 (en) 2019-05-20 2020-11-26 H. Lundbeck A/S New solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
DE3280252D1 (de) 1981-10-16 1990-10-31 Sandoz Ag 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)chinolin-derivate mit pharmazeutischer wirkung.
PH22782A (en) 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
US6410664B1 (en) 1997-03-24 2002-06-25 Cryovac, Inc. Catalyst compositions and processes for olefin polymers and copolymers
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
WO2002013827A1 (en) 2000-08-11 2002-02-21 Purdue Research Foundation Process for the preparation of dinapsoline
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
EP1414457B1 (en) 2001-08-10 2007-06-20 Purdue Research Foundation Chiral dinapsoline
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
KR20050008658A (ko) 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1699450A4 (en) 2003-12-23 2009-11-11 Darpharma Inc Simultaneous administration of dopamine receptor bindings
AU2005232748A1 (en) 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
US20070254906A1 (en) 2004-07-21 2007-11-01 Darpharma, Inc. Method of Administration of Dopamine Receptor Agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
CN102131790A (zh) 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药
TW201036949A (en) 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP3445346A1 (en) 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN116568672B (zh) 2020-11-17 2026-03-24 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101917A1 (en) 2017-11-24 2019-05-31 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234271A1 (en) 2019-05-20 2020-11-26 H. Lundbeck A/S A process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
WO2020234272A1 (en) 2019-05-20 2020-11-26 H. Lundbeck A/S New solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases

Also Published As

Publication number Publication date
WO2020234274A1 (en) 2020-11-26
US20220213071A1 (en) 2022-07-07
CN113727979B (zh) 2024-09-20
US12384765B2 (en) 2025-08-12
EP3972970A1 (en) 2022-03-30
JP2022533913A (ja) 2022-07-27
CN113727979A (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
JP7641234B2 (ja) パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7562562B2 (ja) パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7443606B2 (ja) パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7514859B2 (ja) パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7509803B2 (ja) （２Ｓ，３Ｓ，４Ｓ，５Ｒ，６Ｓ）－３，４，５－トリヒドロキシ－６－（（（４ａＲ，１０ａＲ）－７－ヒドロキシ－１－プロピル－１，２，３，４，４ａ，５，１０，１０ａ－オクタヒドロベンゾ［ｇ］キノリン－６－イル）オキシ）テトラヒドロ－２Ｈ－ピラン－２－カルボン酸の製造方法
KR102935865B1 (ko) (2s,3s,4s,5r,6s)-3,4,5-트리하이드록시-6-(((4ar,10ar)-7-하이드록시-1-프로필-1,2,3,4,4a,5,10,10a-옥타하이드로벤조[g]퀴놀린-6-일)옥시)테트라하이드로-2h-피란-2-카복실산의 새로운 고체 형태
JP7624932B2 (ja) （２Ｓ，３Ｓ，４Ｓ，５Ｒ，６Ｓ）－３，４，５－トリヒドロキシ－６－（（（４ａＲ，１０ａＲ）－７－ヒドロキシ－１－プロピル－１，２，３，４，４ａ，５，１０，１０ａ－オクタヒドロベンゾ［ｇ］キノリン－６－イル）オキシ）テトラヒドロ－２Ｈ－ピラン－２－カルボン酸及びその中間体の製造方法
EA041603B1 (ru) Пролекарства на основе катехоламина для применения в лечении болезни паркинсона

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250221

R150 Certificate of patent or registration of utility model

Ref document number: 7641234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150